Streetbeat News

Price Targets

ENLV

EF Hutton analyst Jason Kolbert has reiterated a Buy rating for Enlivex Therapeutics (NASDAQ:ENLV) and maintained a price target of $13.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 6:38 pm

DAVE

Barrington Research analyst Gary Prestopino has reiterated an 'Outperform' rating for Dave (NASDAQ:DAVE) and maintained a price target of $65.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 6:33 pm

ADEA

BWS Financial analyst Hamed Khorsand has reiterated a Buy rating on Adeia (NASDAQ:ADEA) with a maintained price target of $16.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 6:31 pm

STRA

Barrington Research has reiterated its 'Outperform' rating for Strategic Education (NASDAQ:STRA) with a maintained price target of $135, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 6:28 pm

SIRI

Citigroup analyst Jason Bazinet maintains a Sell rating on Sirius XM Holdings and adjusts the price target to $21 from $2.8, reflecting a reverse stock split of 1:10.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 6:19 pm

EMR

Emerson Electric's stock price is rising following Oppenheimer's decision to increase its price target from $120 to $125.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 6:14 pm

THO

Citigroup analyst James Hardiman maintains a Buy rating on Thor Industries and raises the price target from $119 to $124.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 6:14 pm

MU

Rosenblatt analyst Hans Mosesmann maintains a Buy rating on Micron Technology and raises the price target from $225 to $250.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 6:12 pm

META

Rosenblatt analyst Barton Crockett has maintained a Buy rating on Meta Platforms and raised the price target from $643 to $811, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 6:10 pm

VRDN

Viridian Therapeutics shares rose following BTIG's increase of its price target from $56 to $61.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 5:57 pm